CCO Slideset

HCV Epidemiology and Impact on Intravenous Drug User Risk and Screening

Source: HCV and Methadone Maintenance

HCV Epidemiology and Impact on Intravenous Drug User Risk and Screening


Program Director: Diana L. Sylvestre, MD

Faculty:

  • David L. Thomas, MD, MPH

CME CREDIT INFORMATION

Release Date: 05/18/07

Expiration Date: 05/17/08


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.0 contact hour (0.1 CEUs)

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize the epidemiology and public health importance of HCV
  • Identify routes of HCV transmission, risk factors, and patient populations at high risk for HCV infection
  • Translate clinical implications and strategies to reduce HCV transmission risk
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Supported by an educational grant from

Educational grants support only the CME-certified components of this program.